Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited has allotted 12,665 equity shares of Re.1 each on February 17, 2026 to eligible employees following the exercise of stock options. These options were granted under the Dr. Reddy’s Employees Stock Options Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.
The shares were exercised at prices ranging from Re.1 to Rs. 735.80 per share, and the new shares rank pari passu with existing equity shares. After this allotment, total issued shares are 83,46,44,020 and total issued share capital is Rs. 83,46,44,020, with paid-up capital of 83,46,43,020 equity shares of Re.1 each.
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference organized by Kotak Institutional Equities. The meetings are scheduled in Mumbai on 23 February 2026, will be held in person, and structured as group meets from 09:00 to 17:00 IST. The company notes the schedule may change if required by either the investors or the company.
Dr. Reddy’s Laboratories Limited has filed a Form 6-K to report that Mr. Sushrut Kulkarni, Global Head of IPDO and Senior Management Personnel, has resigned. He will cease employment and senior management responsibilities effective from the close of business on May 8, 2026, as he plans to explore opportunities outside the company.
The company states that the disclosure is made under Regulation 30 of the SEBI Listing Regulations, with required details provided in an annexure. In his resignation letter, Mr. Kulkarni undertakes to support the company during his notice period and ensure a smooth handover of responsibilities.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule for an upcoming investor interaction. The company’s management plans to participate in a Nuvama-organized investor conference in Mumbai on 9 February 2026, holding in-person group meetings from 09:00 to 17:00 IST. The company notes that this schedule may change if required by either the investors or the company.
Dr. Reddy’s Laboratories reported Q3 FY26 results showing modest overall growth but pressure on earnings. Revenue grew 4.4%, driven by double-digit gains in base businesses excluding Lenalidomide and supported by favourable foreign exchange.
Reported EBITDA margin was 23.5%, including a one-time provision from changes in Indian Labour Codes; excluding this, margin was 24.8%. Profit before tax was ₹ 1,543 crores, with a 17.7% PBT margin, or 19% without the labour provision. Profit after tax attributable to equity holders was ₹ 1,210 crores, down 14% year-over-year and 16% sequentially, at 13.9% of revenues.
India revenue reached ₹ 1,603 crores, up 19% year-over-year, supported by innovation brands, new launches, price increases, higher volumes and the acquired Stugeron portfolio. The company ended the quarter with a net cash surplus of ₹ 3,069 crores and generated free cash flow of ₹ 374 crores, while preparing for Semaglutide launches and advancing biosimilar programs such as Abatacept and Denosumab.
Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a tax audit decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia dated January 23, 2026. The authority reclassified certain marketing services as taxable, levying Value Added Tax (VAT) and quantifying a penalty of Rub million 20.09, stated as INR 24.50 million.
The company states that, based on its evaluation, this tax decision has no material impact on its financials, operations, or other activities. Dr. Reddy’s plans to evaluate filing a reply with the Russian tax authority in response to the decision and is providing this update to stock exchanges in India and the New York Stock Exchange.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share an audio recording of its earnings call for the quarter ended December 31, 2025. The call was conducted on January 21, 2026, and the company has provided a web link to the full audio recording for investors and exchanges.
The notice has been sent to the National Stock Exchange of India, BSE, New York Stock Exchange, and NSE IFSC, underscoring that this is a formal communication of the recorded earnings discussion for regulatory and investor information purposes.
Dr. Reddy’s Laboratories Limited filed a Form 6-K as a foreign private issuer, providing an intimation dated January 21, 2026. The company has circulated a presentation on its unaudited financial results for the quarter ended December 31, 2025 to the National Stock Exchange of India, BSE, the New York Stock Exchange, and NSE IFSC.
The filing itself does not reproduce the financial figures, but formally records that these quarterly unaudited results have been prepared and shared with the stock exchanges for information and record purposes.
Dr. Reddy’s Laboratories reported steady growth for Q3FY26 and the nine months ended December 31, 2025. Consolidated Q3 revenues were ₹87,268 million, up 4.4% year-on-year but slightly lower sequentially, while 9MFY26 revenues reached ₹260,771 million, an 8% increase from the prior year. Growth was broad-based across India, Europe, Emerging Markets and PSAI, but North America declined mainly due to lower Lenalidomide sales and pricing pressure.
Profitability softened as the business mix shifted. Q3 gross margin fell to 53.6% from 58.7% a year earlier, and EBITDA margin declined to 23.5% from 27.5%. For 9MFY26, EBITDA was ₹66,787 million, down 1% year-on-year, and profit before tax was ₹52,826 million, down 7%, with profit attributable to equity holders essentially flat at ₹40,649 million. Diluted EPS for 9MFY26 was ₹48.78.
The company continues to invest in branded franchises and R&D, while noting one-time costs from changes in Indian labour codes. The balance sheet remains strong, with cash and investments of ₹87,191 million, loans and borrowings of ₹67,732 million, equity of ₹375,756 million, a net cash surplus of ₹30,677 million and an annualised RoCE of 20.4% as of December 31, 2025.
Dr. Reddy’s Laboratories reports stable results for the nine months ended December 31, 2025. Revenues rose to Rs.260,771 million from Rs.240,475 million, driven mainly by the Global Generics segment, which contributed Rs.233,231 million. PSAI added Rs.25,649 million and Others Rs.1,891 million.
Profit for the period was Rs.40,261 million versus Rs.41,373 million a year earlier. Basic EPS for equity holders was Rs.48.83 for the nine months. For the third quarter, revenues reached Rs.87,268 million and profit was Rs.11,896 million.
The balance sheet remains strong with total assets of Rs.562,899 million, equity of Rs.375,756 million and cash and cash equivalents of Rs.18,657 million. Operating cash flow improved to Rs.41,110 million. The company continues to invest in property, plant, equipment and intangibles while managing moderate short-term and lease-related borrowings.